Lanzhou Foci Pharmaceutical Co.Ltd(002644)
Semi annual report for 2021
Updated in March 2022
Section I important tips, contents and definitions
The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee that the contents of the semi annual report are true, accurate and complete, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities.
Shi Aiguo, the person in charge of the company, Yao Yilei, the person in charge of accounting, and Xu xiankai, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in this semi annual report.
All the reports of the board of directors have been considered.
The company has analyzed the possible risk factors and Countermeasures for the development of the company in “section III discussion and analysis of operation” of this report. Please pay attention to them.
The company plans not to distribute cash dividends, bonus shares or increase share capital with provident fund.
catalogue
Section I important tips, contents and definitions Wrong! No bookmarks defined. Section II Company Profile and main financial indicators Wrong! No bookmarks defined. Section III Management Discussion and Analysis Section 4 corporate governance Section V environmental and social responsibility Section VI important matters Section VII changes in shares and shareholders Section VIII preferred shares Section 9 relevant information of bonds Section x financial report 3 error! No bookmarks defined.
Directory of documents for future reference
(I) the text of the financial report with the signatures and seals of the legal representative, the person in charge of accounting and the person in charge of the accounting institution; (II) originals of all company documents and announcements publicly disclosed during the reporting period; (III) the original copy of the 2021 semi annual report signed by the chairman of the company.
interpretation
Explanatory item refers to the explanatory content
Company / the company refers to Lanzhou Foci Pharmaceutical Co.Ltd(002644)
The articles of association refers to Lanzhou Foci Pharmaceutical Co.Ltd(002644) articles of association
Company Law refers to the company law of the people’s Republic of China and its amendments
“Securities Law” refers to the securities law of the people’s Republic of China and its amendments
The reporting period / current reporting period refers to the first half of 2021
Lanzhou New Area Project / new area project refers to the project of Lanzhou New Area Lanzhou Foci Pharmaceutical Co.Ltd(002644) science and Technology Industrial Park
Fuci group refers to Lanzhou Fuci Pharmaceutical Industry Development Group Co., Ltd
Health industry company refers to Lanzhou Fuci Health Industry Co., Ltd
Chinese herbal medicine management company refers to Gansu foci Chinese Herbal Medicine Management Co., Ltd
Fat Chi Medical Company Limited
Fuci Scientific Innovation Co., Ltd. refers to Lanzhou Fuci Scientific Innovation Co., Ltd
Fuci HongRi sales company refers to Gansu Fuci Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) Sales Co., Ltd
Fuci Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) company refers to Gansu Fuci Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) Co., Ltd
Fuci International Business Co., Ltd. refers to Lanzhou Fuci International Business Co., Ltd
Fuci Medical Technology Co., Ltd. refers to Lanzhou Fuci Medical Technology Co., Ltd
Shanghai foci health Co., Ltd. refers to Shanghai foci Health Technology Co., Ltd
RMB / 10000 yuan / 100 million yuan refers to RMB / 10000 yuan / 100 million yuan
Section II Company Profile and main financial indicators
1、 Company profile
Stock abbreviation Lanzhou Foci Pharmaceutical Co.Ltd(002644) stock code Lanzhou Foci Pharmaceutical Co.Ltd(002644)
Shenzhen Stock Exchange
Chinese name of the company Lanzhou Foci Pharmaceutical Co.Ltd(002644)
Chinese abbreviation of the company (if any) Lanzhou Foci Pharmaceutical Co.Ltd(002644)
Foreign language name of the company (if any) Lanzhou foci Pharmaceutical Co., Ltd
The abbreviation of the company’s foreign name (if any) foci pharmaceutical
The legal representative of the company is Shi Aiguo
2、 Contact person and contact information
Secretary of the board of directors and securities affairs representative
Name: Li Baojun an Wenting
Contact address: No. 2289, Huashan Road, Lanzhou New Area, Lanzhou City, Gansu Province
Tel: 09318362318
Fax: 093183622318
E-mail [email protected]. [email protected].
3、 Other information 1. The company’s contact information, the company’s registered address, the company’s office address and postal code, whether the company’s website and e-mail box have changed during the reporting period □ applicable √ not applicable to the company’s registered address, the company’s office address and postal code, the company’s website and e-mail box have not changed during the reporting period. For details, please refer to the 2020 annual report.
2. Information disclosure and place of preparation whether the information disclosure and place of preparation have changed during the reporting period □ applicable √ not applicable to the name of the information disclosure newspaper selected by the company, the website designated by the CSRC that publishes the semi annual report, and the place of preparation of the semi annual report of the company has not changed during the reporting period. For details, please refer to the 2020 annual report.
4、 Major accounting data and financial indicators does the company need to retroactively adjust or restate the accounting data of previous years □ yes √ no
Increase or decrease in the reporting period over the same period of last year
Operating income (yuan): 3868265375032848663090 17.76%
Net profit attributable to shareholders of listed company (yuan) 47584201 Zhejiang Xinao Textiles Inc(603889) 770753 22.33%
Net profit attributable to shareholders of listed companies after deducting non recurring profits and losses
(yuan) 28577896791870403931 52.79%
Net cash flow from operating activities (yuan) 57946798123 Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) 072 60.92%
Basic earnings per share (yuan / share) 0.093 0.191 – 51.36%
Diluted earnings per share (yuan / share) 0.093 0.191 – 51.36%
Weighted average return on net assets 3.01%, 6.25% – 51.87%
Increase or decrease at the end of the reporting period compared with the end of the previous year
Total assets (yuan): 247666532535238718179219 3.75%
Net assets attributable to shareholders of listed companies (yuan): 156845975704158209069992 – 0.86%
5、 √ differences between the net assets and net profits of the company in the financial reporting period disclosed in accordance with the accounting standards of China and the international accounting standards are not applicable at the same time √ differences between the net assets and net profits of the company in the financial reporting period disclosed in accordance with the accounting standards of China and the international accounting standards are not applicable. 2. At the same time, the difference between the net profit and net assets in the financial report disclosed in accordance with the overseas accounting standards and the Chinese accounting standards □ applicable √ not applicable. There is no difference between the net profit and net assets in the financial report disclosed in accordance with the overseas accounting standards and the Chinese accounting standards in the reporting period. 6、 Non recurring profit and loss items and amount √ applicable □ not applicable
Unit: Yuan
Description of project amount
Government subsidies included in the current profits and losses (closely related to enterprise business, according to the national unified plan)
(I) 2215152179
Profit and loss of entrusting others to invest or manage assets 45937123
In addition to the effective hedging business related to the normal business of the company, it holds trading financial assets, derivative financial assets, trading financial liabilities and derivative financial liabilities
Profit and loss from changes in fair value and disposal of trading financial assets and derivatives -8027808
Investment income from financial assets, trading financial liabilities, derivative financial liabilities and other debt investments
Other non operating income and expenditure other than the above -13376288
Less: income tax impact 338911589
Influence amount of minority shareholders’ equity (after tax) 143137
Total 1900630480–
Information disclosure of the company in accordance with the
